In palmitate-exposed H9c2 cells, 50 µM oroxylin-A for 24 hours increased mitochondrial membrane-potential signal and reduced ROS signals. The authors caution that oroxylin-A is not a very specific sirtuin activator and may have off-target effects. [2]
Oroxylin A did not show chrysin-like p53 acetylation and p21 induction in an MCF7 flavonoid screen at 40 µM for 8 hours. The result is limited to this qualitative immunoblot comparison. [3]
Mitochondrial and oxidative-stress responses in H9c2 cells
Cell-based study · Rat H9c2 cardiomyoblasts exposed to 200 µM palmitate; BSA control and palmitate vehicle comparator [2]
Oroxylin-A co-treatment increased mitochondrial membrane-potential signal and reduced cellular and mitochondrial ROS signals relative to palmitate alone. These are phenotypic responses, without proof of selective SIRT3 engagement.
Literature-Reported Treatment Conditions
- Treatment concentration
- 50 µM Oroxylin-A with 200 µM palmitate
- Exposure duration
- 24 h
- Method
- Cell treatment
- Vehicle
- DMSO; final volume did not exceed 0.2% (v/v)
- Co-treatment
- Oroxylin-A alone with palmitate selected. Separate SRT1720, SRT1720 plus Oroxylin-A, and metformin comparisons were included.
- Reported limits
- Figure captions report n = 3 without defining the replication unit. No direct SIRT3 binding or selectivity assay establishes these phenotypes.
Methods and source locations
Compound reported in the paper: Oroxylin A; Compound label in the paper: Oroxylin-A
Named parent-compound evidence; no salt conversion or validation of the supplied product lot.
Methods 2.1.2–2.1.7; Results 3.11, 3.13; Figures 7A and 9A–B; section 6
Mitochondrial membrane potential: TMRM staining and flow cytometry — Methods 2.1.6; Results 3.11; Figure 7A and caption
Cellular and crude mitochondrial ROS: DCFH-DA and MitoSOX Red fluorescence by flow cytometry — Methods 2.1.3–2.1.4; Results 3.13; Figure 9A–B and caption
Flavonoid comparison reveals a limited p53 response
Cell-based study · MCF7 human breast cancer cells; DMSO negative control, chrysin and adriamycin positive comparisons [3]
Oroxylin A did not show the chrysin-like increase in p53 Lys382 acetylation and p21 in this short-exposure immunoblot screen. This does not exclude other p53 responses at other times or concentrations.
Literature-Reported Treatment Conditions
- Treatment concentration
- 40 µM
- Exposure duration
- 8 h
- Method
- Cell treatment
- Vehicle
- DMSO control; final solvent concentration not stated in the selected experiment
- Co-treatment
- Single-agent flavonoid comparisons; adriamycin 0.3 µM and chrysin 40 µM were comparison treatments, not combinations.
- Reported limits
- Figure 4 does not report n, densitometric values or an uncertainty estimate. No quantitative null-effect size is inferred.
Methods and source locations
Compound reported in the paper: Oroxylin A; Compound label in the paper: Oroxylin A
Named parent-compound evidence; no salt conversion or validation of the supplied product lot.
Results 2.3; Figure 4A and caption; Methods 4.3 and 4.11
p53 Lys382 acetylation and p21 protein response: Immunoblotting for K382Ac, p53, p21 with β-actin loading control — Results 2.3; Figure 4A; Methods 4.3
Cellular LDH-A expression and activity in LX2 cells
Cell-based study · Human LX2 hepatic stellate cell line; comparator labeled Control [1]
Oroxylin A reduced LDH-A mRNA, protein abundance and intracellular enzyme activity. This cellular result does not establish inhibition of purified LDH-A or a direct molecular interaction.
Literature-Reported Treatment Conditions
- Treatment concentration
- 20, 30 and 40 µM
- Exposure duration
- 24 h
- Method
- Cell treatment
- Vehicle
- DMSO used to dissolve the reagent; final concentration not reported in selected text
- Co-treatment
- Single-agent concentration series; genetic and galloflavin experiments were read as context but are not adopted claims.
- Reported limits
- No purified-enzyme IC50 or direct-binding endpoint in this experiment. The statistics section gives at least triplicate experiments without a panel-specific exact n.
Methods and source locations
Compound reported in the paper: Oroxylin A; Compound label in the paper: Oroxylin A
Named parent-compound evidence; no salt conversion or validation of the supplied product lot.
Methods Chemicals and antibodies, Cell culture and transfection, Enzyme activity assay, Statistical analysis; Results Oroxylin a inhibits LDH-A in HSCs; Figure 4a–d
LDH-A mRNA, protein and intracellular enzyme activity: Real-time PCR, immunoblotting, immunofluorescence and cellular enzyme-activity kit — Figure 4a–d and caption; Results Oroxylin a inhibits LDH-A in HSCs; Methods Enzyme activity assay and Statistical analysis